Can Wegovy Cause Depression? What the Evidence Shows

What the clinical evidence actually says about semaglutide and mood

This is the question most people are really asking, and it deserves precision rather than reassurance. In the STEP 1 phase 3 trial (68 weeks, over 1,900 adults with obesity, comparing semaglutide 2.4mg against placebo) depression and suicidal ideation were not identified as treatment-related adverse effects at rates that distinguished the active group from those taking a dummy injection. The NHS medicines page for semaglutide lists the recognised side effects: nausea, vomiting, diarrhoea, constipation, and headache feature prominently. Depression does not appear in the common or uncommon categories.

That does not mean no individual will experience low mood. Individual reports exist, and the MHRA monitors all medicines continuously through the Yellow Card scheme. To date, the MHRA has not published a Drug Safety Update specifically linking Wegovy to depressive illness, in contrast to its January 2026 update on pancreatitis. If new evidence emerges, the prescribing information is updated; any prescriber worth their registration checks the current summary of product characteristics before and during treatment.

There is also a plausible biological nuance worth knowing. GLP-1 receptors exist in the brain, not only the gut, and researchers are actively studying semaglutide's effects on mood, reward pathways and anxiety. Early signals suggest the picture may be more complex than either "causes depression" or "definitely doesn't", which is exactly why this remains a topic of ongoing study rather than settled science. If you want to explore that emerging evidence, our page on whether Wegovy may help with depression covers what the more recent research has found, and our page looking at whether Wegovy can cause depression sets out what the current evidence does and does not show.

The mental health context that surrounds significant weight loss

Here is something that often gets left out of online discussions: losing a substantial amount of weight (by any means, including surgery, intensive diet programmes or GLP-1 therapy) can itself trigger unexpected emotional responses. Identity shifts, changes in how others treat you, the surfacing of feelings that were suppressed alongside eating habits, a drop in appetite that flattens other forms of pleasure for a time. None of that is unique to Wegovy, but it can coincide with it, and the timing creates a plausible-sounding association that is hard to disentangle.

Obesity itself carries a significantly elevated risk of depression; the relationship runs in both directions. That means some people starting Wegovy already have a baseline vulnerability to low mood, and any mood change during treatment may reflect that pre-existing pattern rather than a drug effect. A prescriber considering this is not being bureaucratic. They are doing the risk-benefit work that this clinical decision actually requires.

The NHS England guidance on weight management injections explicitly notes that a patient's mental health history is part of the clinical assessment. If you are currently taking antidepressants, our page on semaglutide alongside depression medication addresses the specific interaction questions that come up most often.

If you're already on Wegovy and your mood has changed

Worry about this is reasonable, not overcautious. The honest answer is that we can't tell you (here, on this page) whether what you're experiencing is a side effect of semaglutide, a natural emotional response to a period of significant physical change, or something unrelated that has coincided with your treatment. That is a clinical judgement, and it requires a conversation with someone who knows your full history.

What you should not do is stop Wegovy abruptly without speaking to your prescriber first. Dose changes and discontinuation decisions need clinical oversight. What you should do, promptly, is get in touch with your care team if low mood is new, persistent or worsening, or if you are having any thoughts of self-harm. NHS 111 is available around the clock, and you can report any suspected side effect directly to the MHRA at yellowcard.mhra.gov.uk.

A question our prescribers hear regularly is whether a mental health history automatically rules out treatment. It does not. Many people with managed depression are assessed as suitable candidates; others are not. The prescriber weighs the benefits of weight management against individual risk factors, and that is a conversation, not a checkbox. If you are wondering whether semaglutide's effects on mood could actually be positive for some people, the evidence on that side of the question is covered on our page exploring what semaglutide research suggests about depression.

What a clinical assessment covers, and where to go next

If you are still deciding whether Wegovy is right for you, the mental health piece is one of several things a prescriber considers alongside your BMI, existing conditions, current medicines and overall health picture. There is no algorithm that replaces that review. At nume, a GPhC-registered Independent Prescriber reads your consultation personally (every time, including repeats) and if mood or mental health is part of your picture, that comes into the conversation rather than being ignored.

You can read more about how semaglutide works and what the full treatment pathway looks like on our Wegovy overview page. If you are further along and want to understand the process of accessing treatment through a regulated online pharmacy, our page on getting Wegovy through a UK pharmacy covers the prescription route and what to expect. The costs involved (and what a legitimate private prescription includes) are laid out honestly on our treatment options page.

Starting, continuing or stopping a prescription medicine when you have concerns about your mental health is not a decision to make on the basis of a forum thread or a search result. Check your eligibility and speak to a prescriber who can look at the whole picture.